Danno K, Colas A, Terzan L, Bordet MF
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from single agonists (Semaglutide) and dual agonists (Tirzepatide)
At higher doses, patients lost an average of nearly a quarter of their body weight, exceeding outcomes typically reported with current licensed treatments such as Wegovy (~15%) or Mounjaro (~20%)
Since compounded products are not FDA-approved, advertisements for them, including on a companys website, should avoid claiming the products are safe or effective for treating any condition
To examine the ion channel mechanisms for the depolarizing responses, we applied small hyperpolarizing current steps during the recording (arrows in Fig
For instance, in the DUAL VII study, 35% of those taking Xultophy achieved an A1C below 7% without hypoglycemia or weight gain, compared to only 5% of participants using basal-bolus insulin